Haemostatic perturbations are commonly seen in extracorporeal membrane oxygenation (ECMO) patients and remain a clinical challenge, contributing significantly to morbidity and mortality. The approach to anticoagulation monitoring and the management of bleeding varies considerably across ECMO centres. Routine laboratory tests have their limitations in terms of turnaround time and specificity of information provided. Newer point-of-care testing (POCT) for coagulation may overcome these issues, as it provides information about the entire coagulation pathway from clot initiation to lysis. It is also possible to obtain qualitative information on platelet function from these tests. Furthermore, the ability to incorporate these results into a goal-directed algorithm to manage bleeding with targeted transfusion strategies appears particularly attractive and cost effective. Further studies are required to evaluate the utility of POCT to optimise bleeding and anticoagulation management in these complex patients.
Introduction
Extracorporeal membrane oxygenation (ECMO) is increasingly used in medical and surgical intensive care units to manage refractory respiratory and/or cardiac failure. While it has traditionally been used in neonatal and paediatric intensive care units (ICUs), advances in extracorporeal technology have broadened its application into adult intensive care 1 . Perturbations in haemostatic function, manifesting as bleeding and thrombotic events, occur in up to 60% of cases and are the most frequently occurring complications of ECMO [2] [3] [4] [5] [6] . While some degree of anticoagulation is essential to minimise clotting in the circuit, the optimal level of anticoagulation is not known and has probably changed after the introduction of centrifugal pumps and heparin-coated tubing.
Despite rigorous monitoring of haemostasis and significant efforts to optimise anticoagulation, patients on ECMO experience profound disturbances in haemostatic function. Variability in haemostatic management across ECMO centres has prevented the establishment of an accepted, standardised approach to this aspect of care.
The recently published anticoagulation guidelines from the Extracorporeal Life Support Organisation (ELSO) recommend every extracorporeal life support program come up with an approach to monitor anticoagulation that works best for the patients in their individual centre, given the number of coagulation assays available and the variable anticoagulation choices and approaches 7 . The literature suggests that conventional laboratory tests of haemostasis are of limited efficacy in ECMO, and may delay detection of haemostatic disorders and often lead to misguided and excessive use of blood products 8 . Viscoelastic testing and platelet function testing may address these issues by providing a more global analysis of haemostasis, encompassing more recent developments in our understanding of the physiology of haemostasis and do so in a timely manner. In this review, we will summarise the physiological mechanisms of haemostasis and briefly review the limitations of standard laboratory haemostatic tests. We then discuss the haemostatic changes that occur during ECMO and highlight some relevant issues in coagulation management. Finally, we discuss these point-of-care testing (POCT) methods that may improve our understanding and management of the haemostatic processes occurring in ECMO patients. within the vasculature. In response to vessel injury, haemostasis typically occurs as a precisely controlled, localised process that balances procoagulant and anticoagulant forces to minimise haemorrhage. Haemostasis has traditionally been divided into three main steps: the initial vascular spasm, the aggregation of platelets to form the platelet plug, and the sequential coagulation cascade that produces thrombin to cleave fibrinogen into fibrin monomers and hence consolidate the platelet plug 9 . This model of haemostasis was based upon in vitro, cell-free studies of plasma. More recent studies present a model that encompasses the cellular contributions to haemostasis (particularly the role of platelets and the endothelium) and a revised understanding of the coagulation cascade 8 .
Haemostasis is initiated by damage to the vascular endothelium and exposure of the blood to the several procoagulant ligands of the subendothelial extracellular matrix. The most significant of these are von Willebrand factor (vWF), tissue factor (TF) and collagen, all of which are potent activators of haemostasis. Collagen and vWF bind to platelet membrane receptors glycoprotein (GP) Ib and IX, which facilitate platelet adhesion and aggregation at the site of injury. Ligand-receptor binding causes platelet activation and degranulation, and the subsequent release of substances such as adenosine diphosphate (ADP), serotonin and thromboxane A2. These molecules in turn further activate platelets and propagate formation of the platelet plug. ADP induces activation of the GP IIb-IIIa receptor on the platelets, which enables platelet binding to fibrinogen. Once platelets become activated, they are able to express phospholipids upon their surface where reactions of the coagulation cascade occur 10 .
These haemostatic processes are equally counteracted by endogenous mechanisms to prevent excessive clot formation. Vascular endothelium inhibits platelet aggregation through expression of nitric oxide and prostacyclin. Coagulation is prevented by endothelial expression of thrombomodulin, heparin and glycosaminoglycans, which express tissue factor pathway inhibitor. Additionally, endothelial cells secrete tissue plasminogen activator (t-PA), a potent thrombolytic agent 11 .
The original model of haemostasis dictates that the coagulation cascade consists of two independently operating cascade reactions; the extrinsic pathway (activated by TF) and the intrinsic pathway. However recent studies show that the tissue factor:Factor VIIa (TF:VIIa) complex (which was originally believed to only be a component of the extrinsic pathway) is responsible for the initial zymogenic activation of both Factors X and IX. Activation of Factor X leads to Factor Xa, which acts in conjunction with Factor V to generate thrombin. TF:VIIa activates Factor IX to Factor IXa, which binds to and activates Factor VIII to produce a IXa:VIIIa complex. This complex can then also activate Factor X and subsequently Factor V to propagate thrombin production.
The acceptance of the original independent coagulation cascades model has led to widespread use of the prothrombin time (PT) to assess the extrinsic pathway and the activated partial thromboplastin time (APTT) for the intrinsic pathway. These tests are performed on citrated, cellfree plasma, and represent the time taken for the formation of fibrin strands 12 . Although these tests indicate the presence of their coagulation factors, they cannot provide a clear stratification of bleeding risk. For example, the absence of Factor XII, whilst causing a significant increase in the APTT, is not associated with an increased risk of bleeding. Conversely, lack of Factor VIII or Factor IX may produce the same prolongation of the APTT but manifests in a severe bleeding tendency 11, 13 . Furthermore, the fact that these tests are performed on cell-free plasma suggests that they do not encompass the cell-based model of haemostasis, omitting the crucial role of platelets. Although the platelet count is a routinely performed test in the laboratory, it does not offer qualitative information about platelet function and aggregation, particularly the ligand-receptor interactions discussed above 12 .
Haemostatic alterations during ECMO
Significant perturbations in haemostatic function are seen during extracorporeal therapies. The causes of these are multifactorial, and may be due to: 1) interactions between the blood and the extracorporeal circuit, 2) patient factors and 3) the effects of anticoagulation. With respect to Virchow's triad, abnormalities may occur across all three limbs of the triad, further highlighting the complexities of haemostasis in ECMO ( Figure 1 ).
Interactions between blood and the extracorporeal circuit
Contact between blood and the foreign surfaces triggers the systemic inflammatory response syndrome (SIRS) 14 . Inflammation and haemostasis are closely interrelated processes, and a key initiating molecule in this phenomenon is TF. During inflammation, activated monocytes and lymphocytes express TF on their cell surface, facilitating overt activation of haemostasis. In ECMO patients, this can manifest as thrombosis, leading to circuit dysfunction or thromboembolic events. These processes are further augmented by the down-regulation of the antithrombin III, protein C and fibrinolytic systems. High levels of circulating tumour necrosis factor alpha and interleukin-1 induce the release of the fibrinolytic agents discussed above; this is however compensated by a prolonged release of plasminogen activator inhibitor 15 . The consequence of this is an absolute inhibition of fibrinolysis. This, combined with diffuse endothelial damage by inflammatory products may manifest as disseminated intravascular coagulation (DIC) 8, [15] [16] [17] , and a resultant consumptive coagulopathy. This effect is more pronounced with the onset of clotting within the oxygenator and resultant damage to red cells.
Platelet dysfunction has been well documented in patients receiving ECMO, cardiopulmonary bypass (CPB), and circulatory support from ventricular assist devices (VADs) 18 . Studies have demonstrated the presence of an acquired von Willebrand syndrome (aVWS), in which the high shear forces within the extracorporeal circuit lead to sequestration and degradation of vWF, hence impairing the activation and aggregation of platelets. This syndrome typically manifests with haemorrhage at the ECMO cannula sites, gastrointestinal tract and nasopharynx [19] [20] [21] . In addition to the aVWS, platelet aggregation has been reported to be reduced during sepsis; particularly through impaired activation of the GP IIb-IIIa receptor 22, 23 .
These findings are supported by our group when haemostatic profiles of adult patients on ECMO were observed 24 . We noted that during ECMO, significant disturbances occurred in platelet function, particularly in the vWF and GP IIb-IIIa mediated pathways.
Patient factors
Multiple patient factors may contribute to bleeding diatheses during ECMO. The most relevant of these are inflammation, sepsis, trauma (and its relevant sequelae), surgery, renal failure and massive transfusion. Furthermore, the time course of ECMO support may be relevant, with haemodilution-related coagulopathy being more significant in the early resuscitation phase, and DIC related to membrane protein deposition in the later phase.
Sepsis may produce alterations in the haemostatic profile. The mechanisms of these are very similar to the changes induced by SIRS (discussed above). The pertinent issues with sepsis are coagulopathy due to DIC, and the procoagulatory mechanisms associated with systemic inflammation. These may be exacerbated during an endotoxaemia, which can lead to further TF expression by damaged endothelial cells and activated monocytes 25, 26 .
Hypovolaemia and reduced tissue perfusion may precipitate endothelial damage and DIC, followed by a consumptive coagulopathy. Therefore trauma and its sequelae have the potential to create an increased propensity for bleeding.
Haemodilution frequently occurs during trauma as a consequence of crystalloid and blood product transfusion. Particularly prominent is dilutional thrombocytopenia 27 . Hypothermia may arise as a result of infusion of inadequately warmed fluids. Reductions in body temperature affect haemostasis at multiple levels including impaired platelet function due to down-regulation of signaling molecules such as thromboxane A2 and inhibition of vWF-mediated aggregation 28 . Hypothermia has also been shown to markedly reduce the zymogenic activity of the coagulation cascade, despite normal concentrations of coagulation factors. At 33°C, Factor IX functions at only 33% of normal 29 . Furthermore, canine studies have indicated an increase in fibrinolysis during hypothermia 30 .
The coagulopathic effects of massive transfusion share many of the same processes as trauma, including haemodilution, hypothermia and alterations in platelet function 31 .
Patients requiring ECMO support who have undergone recent major surgery are at risk of significant bleeding from surgical sites.
Renal dysfunction and resulting uraemia may also contribute to the haemorrhagic diathesis with qualitative platelet dysfunction 32 .
Anticoagulation
To counteract the prothrombotic mechanisms that occur with ECMO, a number of methods are employed. This is primarily achieved through anticoagulation. To minimise the adverse effects of anticoagulation, other approaches may be adopted such as avoiding anticoagulation completely, which may be possible in veno-venous (VV)-ECMO 33 , particularly when using higher ECMO flows, or by aiming for a lower APTT target. The use of intra-aortic balloon counterpulsation along with veno-arterial (VA)-ECMO to reduce afterload and promote cardiac ejection has been advocated by some centres, although this approach is not without risk 34 .
Patients who require ECMO support after major surgery present a major challenge in terms of surgical site bleeding in the early phases and procoagulant tendencies subsequently. Again, periods without anticoagulation, lower-dose anticoagulation and alternative strategies such as the use of specific topical agents such as chitosan granules (Celox) may be required 35 .
In 2013 an ELSO-endorsed international survey of 187 ECMO centres investigated anticoagulation practices 36 . Of the 121 respondents, all centres reported using unfractionated heparin (UFH) for anticoagulation. UFH is inexpensive, has relatively few side-effects, and its short half-life and easy reversibility with protamine make it a very useful anticoagulant 37 . Monitoring is largely based on laboratory tests such as the activated clotting time (ACT) and the APTT. The survey also highlighted marked differences between heparin administration regimens between the centres, which were mainly paediatric. These discrepancies in anticoagulation make it difficult to establish an accepted protocol for the use of heparin in ECMO adult patients. Consequently, over-heparinisation of ECMO patients can manifest in excessive, uncontrollable bleeding and conversely, since ECMO alters heparin pharmacokinetics and potentially increases its rate of clearance, subtherapeutic heparinisation can result in a greater risk of thromboembolic events 38, 39 .
Despite its relatively low side-effect profile, one of the devastating complications of heparin is the heparininduced thrombocytopenia with thrombosis syndrome (HITTS). HITTS occurs in 0.5%-3% of patients receiving UFH, and is a potentially limb-or life-threatening condition, with a mortality of 10%-30% 40, 41 . HITTS arises due to the development of heparin antibodies (usually IgG, but they can also be from the IgM or IgA class) and the formation of immune complexes of heparin, platelet factor 4 and the antibody. The complexes can act as potent platelet activators, and therefore despite patients having a laboratory profile of thrombocytopenia, they are at a greatly increased thromboembolic risk 42 . The diagnosis of HITTS requires a reduction in platelet count of >50% in association with heparin therapy, in combination with laboratory detection of HITTS antibodies 43 . HITTS creates a diagnostic challenge in ECMO due to the several possible causes of thrombocytopenia.
Management requires prompt diagnosis, immediate cessation of any heparin therapy and administration of an alternative anticoagulant. Following a diagnosis of HITTS, anticoagulation is typically achieved using a direct thrombin inhibitor (DTI). Results from the ELSO survey indicate that the three most widely used DTIs are argatroban, bivalirudin and lepirudin. Unfortunately, the data for the use of DTIs for HITTS in ECMO patients is limited. Overall, areas of uncertainty are 1) safe dosing regimens for these drugs in HITTS, and 2) whether they could ultimately replace UFH as the anticoagulants of choice in ECMO. A significant limitation of DTIs, compared to UFH, is the absence of antidotes 44 . It is likely for this reason that UFH remains a more favourable anticoagulant in this patient group.
Monitoring of anticoagulation and haemostasis, and limitations of currently applied techniques
The multifactorial disturbances to haemostasis in ECMO patients necessitate stringent monitoring of haemostasis. Testing is performed routinely to 1) quantify the effects of anticoagulation and 2) stratify bleeding/thrombotic risk.
The ELSO survey indicated that the majority of ECMO centres rely on standard laboratory tests. Unfortunately, similarly to the methods of anticoagulation, it revealed differences in testing methods, therapeutic ranges and testing time intervals 36 .
Currently, most centres rely on the ACT and the APTT to quantitatively assess the effects of heparin. Additional tests including platelet count, plasma fibrinogen concentration (Klauss method) and the PT may also be performed to provide a more global picture. The ACT has been validated for its use in monitoring heparin activity in patients undergoing CPB, however its efficacy is reduced at the lower concentrations of heparin that are typically administered during ECMO 39,45,.46 . Conversely, the APTT has demonstrated greater efficacy at lower concentrations of heparin. However both tests may be prolonged under a number of conditions. The ACT may be prolonged in association with thrombocytopenia, platelet dysfunction, elevated D-dimers, low fibrinogen, coagulation factor deficiencies, hypothermia or haemodilution, while the APTT may be prolonged due to coagulation factor deficiencies, von Willebrand disease, fibrinogen deficiency, alterations in liver function or systemic inflammation 47, 48 . Additionally, APTT assay variability can produce differing levels of sensitivity to heparin therapy which may consequently lead to misguided heparinisation 49, 50 .
During acute haemorrhage in a critically ill patient, standard laboratory tests are further limited in their application due to the significant turnaround times required for results. As discussed above, the use of cell-free plasma negates the contribution of platelets to haemostasis. Furthermore, assays such as the PT, ACT and APTT are performed until fibrin strands are formed 51 . Although these may indicate the presence or absence of coagulation factors, they cannot provide any insight into subsequent haemostatic events, such as hyperfibrinolysis.
The limitations of standard tests of haemostasis have led to some centres employing more specialised laboratory tests of haemostasis. The anti-Factor Xa assay quantitatively assesses the function of heparin by measuring the level of Factor Xa inhibition; it therefore may have a greater correlation with heparin dosing than the ACT or APTT. The data for the anti-Factor Xa assay in ECMO is quite limited, and is predominantly based on retrospective studies in paediatric ECMO patients. Liveris et al retrospectively reviewed 17 paediatric VV-ECMO and VA-ECMO patients to compare the correlations of the ACT, APTT and anti-Factor Xa assay with heparin dosing 52 . Correlations were highest between UFH dose and the anti-Factor Xa assay, and the authors concluded that the anti-Factor Xa assay may be a more reliable indicator of heparin activity. Baird et al retrospectively reviewed 604 consecutive paediatric ECMO patients and evaluated the contributions of the ACT and heparin dose to survival. The authors found that ACT was a poor predictor of survival and was an inadequate assessor of anticoagulation in this population. They recommended that a more functional monitor of heparin such as the anti-Factor Xa assay be investigated 37 . With the limited data available for this test, the anti-Factor Xa assay may have utility as a supplementary test of haemostasis, but at this stage does not have the evidence to replace the APTT or ACT.
In critically ill patients being anticoagulated with a DTI, the ecarin clotting time (ECT) has been shown to be superior to the APTT and ACT for monitoring the action of these agents 53 . There is minimal data for the ECT in patients on ECMO.
The assessment of haemostasis in ECMO therefore poses a significant clinical challenge to the management of these patients. To complicate management further, these challenges of monitoring anticoagulation and evaluating coagulopathies coexist in a unique way and often intensify each other due to consumption of coagulation factors from clotting within the circuit, which itself may result from inadequate anticoagulation.
Given the multifactorial disturbances of haemostasis that can result in haemorrhage during ECMO, standard laboratory haemostatic testing may not precisely identify the underlying cause of the bleeding 37, 54, 55 . Consequently, bleeding events are typically managed with transfusion of coagulation factors guided by laboratory test results and clinician judgement. This non-targeted approach may result in excessive transfusion of blood products, which increases the risk of complications such as transfusion-related acute lung injury, transfusion-related circulatory overload and transfusionrelated immunomodulation [56] [57] [58] as well as thromboembolic complications from a hypercoagulable state due to overcorrection. These additionally lead to increased ICU and hospital length of stay, and markedly increased costs 59 . These challenges in current ECMO management suggest that the monitoring of haemostatic function and the usage of coagulation support products during bleeding require improvement.
Future directions of haemostatic monitoring in ECMO
The inability of conventional laboratory tests to globally assess haemostatic function in ECMO has led to interest in the implementation of POCT into ECMO practice. POCT of haemostasis is able to provide specific information on quantitative and qualitative aspects of haemostasis, such as factor deficiency, hyperfibrinolysis, platelet dysfunction and the effects of heparin. POCT may enable earlier detection and differentiation of haemostatic dysfunction. During bleeding events this may lead to more timely intervention and a more targeted approach to blood product administration. POCT has not been routinely implemented into the haemostatic management of ECMO patients, but its use has been well documented in the fields of cardiothoracic surgery, liver transplantation and trauma 12, 47 . While the PT and APTT can now be performed using point-of-care devices, the POCT we refer to includes viscoelastic tests and tests that qualitatively assess platelet aggregation and function.
Viscoelastic tests
Thromboelastography (TEG®) and rotational thromboelastometry (ROTEM®) are viscoelastic point-of-care devices that have been used for coagulation monitoring. The principal mechanisms behind the devices are very similar. With thromboelastometry, a haemostatic activator is added to a well of whole, citrated blood, and a pin is inserted into the well and slowly rotated. As the pin rotates, fibrin strands form between the pin and the walls of the well, and the device measures the tensile forces produced by these strands. In contrast, with TEG, it is the cup that oscillates and the pin remains stationary, but again it is the tensile forces of the fibrin strands that are measured 60 . Both TEG and ROTEM assess haemostasis from the point at which the activator is added to the blood, until clot lysis.
These devices may consequently overcome many of the limitations encountered with conventional laboratory tests 61 . Firstly, their size and ease of use by clinicians enable haemostatic testing to be performed at the bedside, leading to shorter turnaround times for results. Secondly, as the tests are performed on whole blood, this encompasses the cell-based model of haemostasis. TEG and ROTEM both graphically display all phases of clot formation, clot quality and lysis, the parameters of which are presented in Table 1 . Both devices use a variety of assays to exploit various components of the haemostatic system to specifically identify the coagulation defect (see Table 2 ) 47, 61 . Both methods provide values and reference ranges for the different phases of clotting and clot lysis. The values obtained from either device are not interchangeable and studies have reported poor correlation between the TEG and ROTEM 60 . Clinically, it is important that algorithms and protocols from one method are not used to guide coagulation management for values produced by the other 62, 63 . The reference range devised for ROTEM has been validated in Lang's multicentre study, which demonstrated consistency in the values obtained and no inter-centre variability 64 .
Currently, few studies have investigated the utility of TEG and ROTEM in the context of ECMO.
Alexander et al performed a retrospective review of TEG in a paediatric population receiving ECMO to explore its correlation with standard laboratory tests 65 . A weak relationship was observed between TEG variables and the APTT and ACT. The authors recommended that TEG become an essential component of coagulation monitoring in paediatric ECMO patients. They made particular note of the utility of the heparinase assay as it allows clinicians to profile the patient's coagulation despite the presence of systemic heparin. Davis et al report a paediatric case study of a postoperative cardiac surgery patient who had difficulty weaning from bypass and was consequently transferred to ECMO 66 . At the initiation of ECMO the patient began to bleed extensively at a rate of 400 ml/hr. TEG was used for coagulation profiling, and again the authors made particular note of the ability to discriminate between systemic heparinisation and coagulopathy. Göerlinger et al in 2012 67 recommended the use of point-of-care thromboelastometry and platelet function analysis during mechanical circulatory support (MCS) therapy to reduce the risk of bleeding and thromboembolic complications. They suggested that these tests should be performed repeatedly during MCS therapy since thrombin generation, clot firmness and platelet response may change significantly over time with high inter-and intra-individual variability.
In a recent, small prospective study of the haemostatic profile in adult ECMO patients, the authors guided their management of anticoagulation and bleeding events through the use of conventional laboratory tests 24 . In addition, during the study, daily thromboelastometry and platelet aggregometry assessments of the coagulation profile were performed. In order to predict how POCT may have impacted their management of bleeding events, the authors retrospectively compared their actual usage of coagulation support products with how they would have managed the bleeding had their care been guided by POCT (based on a treatment algorithm modified from Göerlinger et al-see Figure 2 ) 68 . They found that potentially the use of blood products guided by the POCT algorithm would have been lower and different from those used without the knowledge of the POCT results.
Despite the lack of studies investigating the use of POCT of haemostasis in ECMO, several studies have investigated the utility of TEG and ROTEM in cardiac surgery (Table 3 ). These studies indicate that the implementation of POCT for these patients reduces healthcare costs, rationalises usage of blood products and enables earlier diagnosis of haemostatic abnormalities, with no worsening of mortality [68] [69] [70] [71] . Due to the parallels between CPB and ECMO, this suggests that POCT may result in similar outcomes in ECMO patients. However, unlike in cardiac surgery and other surgical contexts where the desire is to normalise coagulation to achieve haemorrhage control, in ECMO and VAD patients, a degree of anticoagulation is required to be maintained to prevent circuit and pump thrombosis. Therefore current published algorithms for POCT may not apply to these situations and further research needs to be made in order to establish evidence-based algorithms for the role of these tests in managing haemostasis during ECMO.
Multiple electrode aggregometry
This is another available point-of-care technology that may be used to complement the use of viscoelastic tests. While quantitative measurement of platelets is easily available in routine laboratory testing, qualitative dysfunction remains of significant clinical interest, particularly in ECMO patients. Platelet function was most commonly assessed using the light transmission aggregometry of platelet-rich plasma introduced by Born in 1962, which remains the gold standard 72, 73 . Disadvantages include the need for centrifugation of the blood, which is known to influence platelet function 72 .
To enable improved understanding of platelet function in whole blood, methods like single platelet counting (SPC) and whole blood impedance were introduced. Although SPC is widely used it is a labour-intensive technique. Furthermore it is not possible to assess the clot itself, since it works by counting the loss of free platelets. Whole blood impedance aggregometry was introduced by Cardinal and Flower in 1980 72, 74 . It is based on the change of impedance proportional to the number of platelets adhering to a pair of electrodes. A further development of this method is multiple electrode aggregometry (MEA) (Multiplate® analyser, Dynabyte Medical, Munich, Germany). It has five channels for parallel preparations and uses two pairs of electrodes per chamber. Either citrate-or hirudin-anticoagulated blood is used; though there is a significantly higher platelet aggregation measured by MEA in hirudin-anticoagulated blood than in citrate-anticoagulated blood 72, 75 . There are six different assays available to test for the different receptor pathways of platelet activation (Table 3 ). By adding one activator to each chamber, the corresponding pathway is tested: ADP-induced test (ADPtest) looking for inhibitors to the ADP receptor like clopidogrel or prasugrel; an arachidonic acid-induced assay for the cyclooxygenase pathway (ASPItest); the collagen-induced aggregation test (COLtest); TRAPtest using thrombin-receptor-activating-peptide 6 (TRAP-6) as an agonist sensitive to the GP IIb-IIIa receptor pathway and a test for a vWF or GP Ib-dependent aggregation using ristocetin as an agonist (RISTO).
The Multiplate displays the result as two aggregation curves per channel, and calculates the mean values of the two determinations as arbitrary 'aggregation units'.
The Multiplate results reflect platelet function as long as platelets are within the normal range of 150 to 400 x 10 9 /l. When platelet count is below 100 x 10 9 /l there is decreased aggregation 76 , so a minimum platelet count of 100 x 10 9 /l is required for accurate results 77 . Advantages of MEA technology are rapid assessment at the bedside 72, 73, 78 and the small sample sizes 77 . While MEA has been studied in healthy volunteers, in von Willebrand disease 73 , in trauma patients 79 and in platelet inhibition in cardiovascular patients 78 , there are, to our knowledge, no published data on MEA in ECMO patients.
Clinical case scenario
The following case vignette illustrates the utility of POCT during ECMO.
A 48-year-old woman underwent complex, redo multivalvular cardiac surgery for longstanding rheumatic valvular heart disease with pulmonary hypertension. She was on warfarin preoperatively, which was bridged to enoxaparin prior to surgery. Her preoperative renal and hepatic function was normal. The surgery was technically difficult due to extensive calcification and required pericardial patch repairs and a 160-minute CPB time. The patient received four units of fresh frozen plasma, two units of cryoprecipitate and a pool of platelets to manage bleeding. The patient developed worsening right heart failure with haemodynamic instability when weaning off CPB and was placed on peripheral VA-ECMO prior to transfer to ICU.
Unfractionated heparin was commenced via the ECMO circuit on day one, aiming for an APTT of 45-65 seconds (reference range 25-35 seconds).
The course over the next two days was uneventful. However on day three, the patient developed significant bleeding at the arterial ECMO cannula site requiring transfusion of three units of packed cells. ROTEM Retrospective audit to compare blood product usage in CPB patients in the six months prior to implementation of ROTEM, with the 6 months after. Transfusion rates before and after ROTEM:
• RBC transfusion reduced from 60% to 53% (P <0.05) • FFP usage reduced from 17% to 12% (P <0.05) • Plt usage reduced from 16% to 11% (P <0.05) No significant differences in outcomes, length of hospital stay or re-exploration surgery were observed between the groups. RBC = red blood cells, Plt = platelets, FFP = fresh frozen plasma, CPB = cardiopulmonary bypass, ROTEM = rotational thromboelastometry, TEG = thromboelastography, RCT = randomised controlled trial, CABG = coronary artery bypass grafting, POCT = point-of-care testing.
Local pressure and thrombostatic agents were unsuccessful at stopping the bleeding and a plan to return the patient to the operating room for exploration and repair was made. Point-of-care testing with ROTEM ( Figure 3 ) and Multiplate ( Figure 4) Therefore the major abnormality was thought to be platelet based and platelet transfusion was administered. In the absence of adequate platelet response, augmenting fibrinogen (particularly when low normal) would augment the extrinsic pathway response. Therefore, cryoprecipitate was administered as a fibrinogen source. The bleeding responded to these interventions and no further surgery was required.
Future Directions
Over the last few years, anaesthetic and intensive care practitioners are becoming increasingly familiar with incorporating point-of-care coagulation testing and algorithms into their clinical practice in several areas. Further studies are needed to document the haemostatic changes that occur during ECMO since the developments in extracorporeal technology. In addition, the impact on clinical outcomes of incorporating these into management algorithms needs to be evaluated before routine adoption of these tests. In addition, as this approach would add to investigation costs due to the price of reagents, cost-benefit analyses-taking into consideration the potential savings to blood usage-need to be undertaken.
